Ryeqo approved for endometriosis, pending PBS subsidy
Summary: The Therapeutic Goods Administration has approved Ryeqo, the first new treatment for endometriosis in 13 years. The drug, pending PBS subsidy, costs approximately $135 per month. Endometriosis affects one in seven women and causes symptoms like heavy bleeding and severe pain. Ryeqo, a single-pill alternative, is aimed at managing symptomatic endometriosis by suppressing hormone production. However, its high cost may create an economic burden for patients.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings